**Core tip:** This paper is a mini-review that compares the design of the two pivotal trials studying the role of FOLFIRINOX and gemcitabine/nab-Paclitaxel in the management of metastatic pancreatic cancer. It also analyzes the effects these regimens have on toxicity profile, quality of life, real life experiences, choice of second-line therapy and cost.

INTRODUCTION
============

Adenocarcinoma of the pancreas is one of the most aggressive human cancers, ranking fourth among cancer related deaths\[[@B1]\]. Recent biomolecular progress has led to a better comprehension of pancreatic carcinogenesis; however, the revolutionary targeted and immune therapies have not shown any significant results\[[@B2]\]. Subsequently, cytotoxic drugs remain the backbone of treatment for metastatic pancreatic cancer (mPC). Gemcitabine has been the standard of care in mPC since 1996, providing a limited survival of six months due to the intrinsic capacity of cancer cells and the surrounding microenvironment to resist cytotoxicity\[[@B3]-[@B5]\]. More aggressive regimens were developed to overcome these resistance mechanisms. The combination of non-cross resistant agents, GTX (gemcitabine, docetaxel and capecitabine) and PEFG (cisplatin, epirubicin, fluorouracil and gemcitabine), enhanced tumor shrinkage by acting on different stages of cell cycle and bypassing mechanisms of drug resistance\[[@B6]-[@B8]\].

In 2011, French investigators from the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup published the results of a phase II/III trial that revealed a clinically significant survival benefit and better quality of life for a regimen combining 5-FU/leucovorin, oxaliplatin and irinotecan (FOLFIRINOX) at the expense of increased toxicity\[[@B9]\]. Another option is nab-paclitaxel, which is a second generation chemotherapy agent that exploits the ability of albumin to deliver the hydrophobic molecule, paclitaxel, to targeted tissues. Nab-paclitaxel was combined with gemcitabine in the multinational MPACT phase III trial and added an OS benefit of 2.6 mo compared to single agent Gemcitabine\[[@B10],[@B11]\]. Table [1](#T1){ref-type="table"} summarizes the efficacy of the FOLFIRINOX and gemcitabine/nab-paclitaxel (GNP) as published in the pivotal studies of ACCORD/PRODIGE and MPACT trials, respectively.

###### 

Comparison of the pivotal studies approving FOLFIRINOX and gemcitabine/nab-paclitaxel in metastatic pancreatic cancer

                                                        **ACCORD/PRODIGE trial (FOLFIRINOX )\[[@B9]\]**   **MPACT trial (GNP)\[[@B10]\]**
  ----------------------------------- ----------------- ------------------------------------------------- ---------------------------------
  Study characteristics               Duration          December 2005-October 2009                        May 2009-April 2012
  Location                            France            Multinational                                     
  Number of patients                  342               861                                               
  Study design                        Phase 2-3         Phase 3                                           
  Control arm                         Gemcitabine       Gemcitabine                                       
  Patient and tumor characteristics   Median age        61 years                                          62 years
  Sex distribution                    Male (62%)        Male (57%)                                        
  ECOG                                PS 0 (37.4%)      KPS 100 (16%)                                     
  PS 1 (61.9%)                        KPS 80-90 (77%)                                                     
  PS 2 (0.6%)                         KPS 60-70 (7%)                                                      
  Tumor stage                         Metastatic        Metastatic                                        
  Metastatic sites                    Liver (87.6%)     Liver (85%)                                       
  Lung (19.4%)                        Lung (35%)                                                          
  Peritoneum (19.4%)                  Peritoneum (4%)                                                     
  Tumor location                      Head (39.2%)      Head (44%)                                        
  Response                            ORR (%)           31.6                                              23
  PR (%)                              31                23                                                
  SD (%)                              38.6              27                                                
  DCR (%)                             70.2              48                                                
  PFS (mo)                            6.4               5.5                                               
  OS (mo)                             11.1              8.5                                               
  1-yr OS (%)                         48.4              35                                                
  Safety (Grade 3-4 toxicities)       Neutropenia       45.7                                              38
  Febrile neutropenia                 5.4               3                                                 
  Thrombocytopenia                    9.1               13                                                
  Anemia                              7.8               13                                                
  Fatigue                             23.6              17                                                
  Peripheral neuropathy               9                 17                                                
  Diarrhea                            12.7              6                                                 
  Side effects                        Toxic death       0.6                                               4
  Alopecia                            11.2              50                                                
  G-CSF use                           42.5              26                                                

DCR: Disease control rate; GNP: Gemcitabine/nab-paclitaxel; PR: Partial response; ORR: Overall response rate; OS: Overall survival; SD: Stable disease.

The best choice for first-line therapy is a matter of debate. The National Comprehensive Cancer Network (NCCN) panel considers FOLFIRINOX as the first choice for *Eastern Cooperative Oncology Group (*ECOG) 0-1 patients given its lower HR for death, whereas nab-paclitaxel should be reserved for ECOG 2 patients (NCCN 2016). Conversely, ASCO and ESMO consider both regimens as acceptable treatment options for ECOG 0-1 patients\[[@B12],[@B13]\]. Indirect comparisons using the ESMO magnitude of clinical benefit scale show a higher score for the FOLFIRINOX regimen when compared to GNP (5/5 *vs* 2/5, with a higher score indicating a better regimen in terms of survival benefit and quality of life)\[[@B14]\]. In addition, a Bayesian meta-analysis comparing multiple systemic protocols in advanced pancreatic cancer showed a trend toward better survival with FOLFIRINOX compared to GNP\[[@B15]\]. In view of this debate, we conducted this review to discuss the main comparison points between FOLFIRINOX and GNP, including the design of the two pivotal trials, toxicity profiles, quality of life, real life experiences, choice of second-line therapy and cost effectiveness.

TRIAL DESIGN: PRODIGE *VS* MPACT
================================

The PRODIGE and MPACT trials were both randomized controlled trials (RCTs) based on an intent to treat principle and included 342 and 861 patients with mPC, respectively. Both trials had nearly the same tumor characteristics\[[@B9],[@B16]\]. Additionally, the median age (61 years for both trials) and sex ratio (1.6 for PRODIGE and 1.3 for MPACT) were nearly identical. However, the French trial included only patients less than 76 years old with good performance status based on the ECOG evaluation system (ECOG 0-1). In contrast, the MPACT trial did not specify an age limit (age ranged from 27 to 86 years) and included patients with intermediate performance status based on the KPS system (KPS \< 90 in nearly 42% of patients). In addition, the PRODIGE trial only included patients from French centers while the MPACT trial was a multinational study including patients from North America (63%), Australia (14%), and Eastern (15%) and Western Europe (9%). In addition, patients in the Gemcitabine arm of the PRODIGE trial received only 6 mo of therapy even if they were not progressing (17%), nearly half of whom did not continue. While some authors do not consider these differences important given that the survival curves of the gemcitabine arm in the two trials are "superimposable", others do not share this opinion. In fact, Gemcitabine is a well-known drug that is tolerated in the elderly population, even in intermediate health systems such as that of Eastern Europe. The same is not true when a new drug such as nab-paclitaxel is added to gemcitabine. In fact, the forest plot in the MPACT study clearly shows an effect of age and country on hazard ratio. In the same sense, Tehfe et al\[[@B17]\] published an analysis of patients from Canada (a sub-group of the MPACT trial) and showed an OS equal to 11.9 mo in the GNP arm compared to 7.1 mo in the gemcitabine arm with a hazard ratio of 0.76. However, this subgroup analysis included only 63 patients and was underpowered to detect a statistically significant result.

TOXICITY AND QUALITY OF LIFE
============================

The toxicity profile of a chemotherapy regimen is a major contributor in its adoption. Based on the two trials, hematologic toxicity is in favor of the FOLFIRINOX regimen and includes a lower incidence of neutropenia (45% *vs* 38%) (although the use of G-CSF was more common), anemia (7.8% *vs* 13%), and thrombocytopenia (9.1% *vs* 13%). The remaining toxicities are listed in Table [1](#T1){ref-type="table"}\[[@B9],[@B16]\]. Peripheral neuropathy attributed to Nab-paclitaxel is a particular debilitating toxicity; grade 3 peripheral neuropathy was encountered in 17% of the patients but improved to grade 1 toxicity or less in a median of 29 d\[[@B10]\]. Real-life studies with a closer follow-up of patients showed fewer side effects compared to those reported in the clinical trials\[[@B18]\]. Chemotherapy-induced hair loss is often a major determinant of the treatment regimen selected and was more commonly encountered in the GNP regimen (50% *vs* 11.2%)\[[@B9],[@B16]\].

Overall, FOLFIRINOX remarkably improved global health status, emotional functioning and many of the symptoms of mPC, such as pain and anorexia (although FOLFIRINOX did not relieve diarrhea), in the first two months of treatment. It also showed significantly increased time to physical or cognitive deterioration\[[@B19]\]. On the other hand, quality of life was not assessed in the MPACT trial. In contrast, GNP showed significant improvement in quality-adjusted survival in comparison to gemcitabine alone using the Quality-Adjusted Time Without Symptoms or Toxicities (Q-TWiST) methodology, despite the limitations of the Q-TWiST analysis and the lack of prospective quality of life data from the MPACT trial\[[@B8]\].

Because significant toxicity was not uncommon, more tolerable treatment regimens were created by modifying the administration or drug dosing schedule. In the modified FOLFIRINOX regimens, either the 5-fluorouracil bolus was omitted or the dose of irinotecan was reduced. Stein et al\[[@B20]\] published solid data in a prospective study, enrolling both locally advanced and mPC patients who received a modified FOLFIRINOX regimen including a 25% dose reduction in 5-FU or irinotecan. These modifications successfully maintained the efficacy of the drugs while significantly decreasing the toxicity profile (decreased neutropenia, vomiting and fatigue). Additional exploratory analyses of the MPACT trial showed that patients who had dose delays or reductions (71% and 41%, respectively) had better outcomes\[[@B8]\]. These practical changes are capable of modifying the tolerance profile of the drugs while preserving efficacy. Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"} compare the classical to the modified form of FOLFIRINOX and GNP respectively\[[@B20]-[@B23]\].

###### 

Comparison of the FOLFIRINOX and modified FOLFIRINOX trials

                                                                    **ACCORD/PRODIGE trial (FOLFIRINOX)\[[@B9]\]**   **Stein et al\[[@B20]\] Modified FOLFIRINOX**      **Mahaseth et al\[[@B21]\] (Modified FOLFIRINOX)**   **Ghorani et al\[[@B22]\] (Modified FOLFIRINOX)**
  ----------------------------------- ----------------------------- ------------------------------------------------ -------------------------------------------------- ---------------------------------------------------- -----------------------------------------------------
                                      Location                      France                                           United States                                      United States                                        United Kingdom
  Number of patients                  342                           44                                               36                                                 18                                                   
  Study design                        Phase 2-3 Prospective         Phase 2 Prospective                              Phase 2 Prospective                                Retrospective                                        
  Study design                        Dosing                                                                         25% reduction in bolus 5-FU and irinotecan doses   No 5-FU bolus                                        No 5-FU bolus and 25% reduction in irinotecan doses
  Patient and tumor characteristics   Median age                    61 years                                         62                                                 63                                                   60
  Sex distribution                    Male (62%)                    Male (56.8%)                                     Male (56.8%)                                       Male (44.6%)                                         
  ECOG                                PS 0 (37.4%)                  PS 0 (46%)                                       PS 0 (22%)                                         PS 0 (56.6%)                                         
  PS 1 (61.9%)                        PS 1 (54%)                    PS 1 (76%)                                       PS 1 (44.4%)                                                                                            
  PS 2 (0.6%)                                                       PS 2 (1%)                                                                                                                                                
  Tumor stage                         Metastatic                    Metastatic                                       Metastatic                                         Locally advanced and metastatic                      
  Metastatic sites                    Liver (87.6%)                 Liver (54.1%)                                                                                                                                            
  Lung (19.4%)                        Lung (32.4%)                                                                                                                                                                           
  Peritoneum (19.4%)                  Peritoneum (37.8%)                                                                                                                                                                     
  Tumor location                      Head (39.2%)                  Head (54.8%)                                     NA                                                 Head (566%)                                          
  Response                            ORR (%)                       31.6                                             35.1                                               30                                                   47
  PR (%)                              31                            35.1                                             NA                                                 47                                                   
  SD (%)                              38.6                          51.5                                             NA                                                 23                                                   
  DCR (%)                             70.2                          86.6                                             NA                                                 80                                                   
  PFS (mo)                            6.4                           6.1                                              8.5                                                7.2                                                  
  OS (mo)                             11.1                          10.2                                             9                                                  9.3                                                  
  1-yr OS (%)                         48.4                          38                                               NA                                                 NA                                                   
  Safety (grade 3-4 toxicities)       Neutropenia                   45.7                                             12.2                                               3                                                    0
  Febrile N.                          5.4                           4.1                                              0                                                  5.6                                                  
  Thrombocytopenia                    9.1                           9.5                                              4                                                  0                                                    
  Anemia                              7.8                           5.4                                                                                                 0                                                    
  Fatigue                             23.6                          12.2                                             13                                                 5.6                                                  
  Peripheral neuropathy               9                             2.7                                              4                                                  0                                                    
  Diarrhea                            12.7                          16.2                                             13                                                 16.7                                                 
  Toxic death                         0.6                           0                                                0                                                  0                                                    
  Additional information              Pegfilgastrim on each cycle   Pegfilgastrim on each cycle                      Pegfilgastrim on each cycle                                                                             

DCR: Disease control rate; PR: Partial response; ORR: Overall response rate; OS: Overall survival; SD: Stable disease.

###### 

Comparison of the gemcitabine/nab-paclitaxel and modified gemcitabine/nab-paclitaxel trials

                                                         **MPACT trial\[[@B10]\] (GNP)**   **Krishna et al\[[@B23]\] (Modified GNP)**
  ----------------------------------- ------------------ --------------------------------- --------------------------------------------
  Study design                        Location           International                     United States
  Number of patients                  861                49                                
  Dosing                                                 Omission of Day 7 doses           
  Study design                        Phase 3            Retrospective                     
  Patient and tumor characteristics   Median age (yr)    62                                65
  Sex distribution                    Male (57%)         Male (57%)                        
  Tumor stage                         Metastatic         Metastatic                        
  Metastatic sites                    Liver (85%)        Liver (57%)                       
  Lung (35%)                          Lung (27%)                                           
  Peritoneum (4%)                     Peritoneum (43%)                                     
  Tumor Location                      Head (44%)         Head (51%)                        
                                      PFS (mo)           5.5                               4.8
  OS (mo)                             8.5                11.1                              
  Safety (Grade 3-4 toxicities)       Neutropenia        38                                10
  Thrombocytopenia                    13                 4                                 
  Anemia                              13                 15                                
  Fatigue                             17                 6                                 
  Peripheral neuropathy               17                 2                                 
  Diarrhea                            6                  0                                 

GNP: Gemcitabine/nab-paclitaxel; OS: Overall survival; PFS: Progression free survival.

CHOICE OF SECOND-LINE
=====================

The optimal treatment sequence dictates the choice of first-line treatment for mPC. In fact, in the PRODIGE trial, only 47% of the patients were fit enough to receive second-line therapy while only 12.5% of patients received a second-line therapy after initially receiving a gemcitabine-based combination, yet the median OS was limited to 4.4 mo among those receiving second-line treatments. On the other hand, in the MPACT trial, 40% of the patients received additional therapy after GNP\[[@B24]\]. According to these data, similar numbers of patients were able to receive second-line therapy after either FOLFIRINOX or GNP.

Data on the administration of GNP after FOLFIRINOX failure in the literature is limited to a few retrospective studies with conflicting data. The AGEO trial, a prospective multicenter study, evaluated the use of GNP in the second-line setting after FOLFIRINOX failure. The disease control rate was 58% with a 17.5% overall response rate and OS of 8.8 mo. Twelve patients (21%) had an ECOG of 2, and 40% had grade 3-4 toxicities without any treatment-related deaths\[[@B25]\]. In another retrospective study by Zhang et al\[[@B26]\], 28 patients treated with the same regimen showed less satisfactory results, with an OS of 23 wk.

Small retrospective studies assessed the efficacy of FOLFIRINOX in the second line setting with a modest improvement in OS, but none evaluated its efficacy after GNP\[[@B27],[@B28]\]. In fact, the only data available is from the exploratory analyses of the second line treatment of the MPACT trial, where FOLFIRINOX (despite demonstrating interesting data) was only administered to 18 patients (10.5% of the whole population), calling the use of this treatment sequence into question\[[@B16]\].

Consequently, definitive recommendations concerning the optimal sequence of therapy cannot be made. The prospective data from the AGEO trial makes GNP a better and more plausible option as a second-line option after FOLFIRINOX administration. However, large RCTs are needed to create newer guidelines.

COST-EFFECTIVENESS
==================

In addition to weighing efficacy and safety, oncologists must evaluate financial considerations to choose the optimal chemotherapy regimen. In fact, the NCCN shows a tendency toward incorporating the financial burden of cancer drugs into its decision-making strategy. Cost-effectiveness of each regimen is largely dependent on the societal willingness-to-pay (WTP) threshold set by each country. For instance, setting the WTP in Canada at \$130000 makes the FOLFIRINOX regimen the optimal strategy in mPC. However, decreasing the limit to \$80000 renders Gemcitabine monotherapy the only possible therapeutic choice\[[@B29]\]. Similarly, the increased WTP threshold in Greece rendered the GNP protocol a potential option in the treatment of patients with mPC\[[@B30]\].

Both FOLFIRINOX and GNP showed consistent cost-effectiveness and cost-utility with superior survival efficacy in independent analytical studies\[[@B31],[@B32]\]. However, it is not until recently that the values of each regimen were compared. The value of the different regimens in mPC was compared based on Medicare rates, which take into consideration the cost and administration of the drug, hospitalization and management of associated adverse events. The monthly costs of FOLFIRINOX and GNP were \$7234 and \$12221 respectively. However, the cost of the overall treatment based on progression free survival in each protocol was estimated at \$46289 and \$67216. FOLFIRINOX seemingly exhibits higher cost-effectiveness than GNP according to these results. However, it is worth mentioning that the cost of the FOLFIRINOX regimen is mainly due to its toxicity profile. Dosing modifications could limit the incidence of serious side effects and thus further increase the cost-effectiveness of this protocol (Monthly cost of FOLFIRINOX is \$763 versus \$9008 for the GNP protocol). Consequently, in September 2015, the National Institute for Health and Care Excellence recommended against the use of GNP in patients with mPC due to the limited benefits in comparison to the cost of the drug. An alternative cheaper option that might be considered is modified GNP (which is yet to be validated), which has an overall treatment cost of \$36226\[[@B33]\].

CONCLUSION
==========

Overall, both FOLFIRINOX and GNP result in better overall survival and quality of life. In the absence of direct comparison, the treatment choice for patients with mPC is determined by physical toxicity and financial cost, both of which favor the FOLFIRINOX regimen. Further studies should aim to evaluate the modified schedules and dosing of both regimens in multinational RCTs and search for biomarkers that predict response to treatment\[[@B34]\]. In addition, the choice of first-line therapy in the future may not be limited to these two regimens, as newly developed drugs/therapeutic strategies should be tested in clinical trials to find more efficacious options for patients with good performance status.
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